{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:03:09Z","timestamp":1784782989626,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Haemophilia B, the result of factor IX deficiency, is a complex clinical condition that is particularly challenging when associated with kidney failure. This is primarily due to the high bleeding risk associated with kidney replacement therapies. The increase in life expectancy in haemophilia patients has resulted in a greater prevalence of age-related comorbidities, including chronic kidney disease. Nevertheless, a consensus has yet to be reached regarding the most suitable dialysis modality for this population. In this report, we present a case study of a 68-year-old male patient suffering from severe haemophilia B, who was administered prophylactic Idelvion\u00ae (albutrepenonacog alfa) and subsequently underwent arteriovenous fistula creation and haemodialysis initiation without encountering any bleeding complications. This narrative review, from the perspective of a nephrologist, addresses the epidemiology and main clinical considerations regarding dialysis in haemophilia B. These considerations include the choice between haemodialysis and peritoneal dialysis, vascular access planning, haemostasis management with factor IX replacement, and anticoagulation strategies aimed at minimising bleeding risk. A review of the extant literature and clinical reports published between 2020 and 2025 was conducted, integrating documented experiences and available guideline recommendations. In addition, we put forward a series of pragmatic recommendations that are \u00adunderpinned by a systematic decision-making framework. Through meticulous multidisciplinary planning incorporating the utilisation of factor IX concentrates, meticulous surgical techniques, and tailored anticoagulation protocols, patients with haemophilia B can be deemed eligible for chronic haemodialysis with a reasonable degree of safety.<\/jats:p>","DOI":"10.1093\/joneph\/aajag131","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:26:57Z","timestamp":1778585217000},"source":"Crossref","is-referenced-by-count":0,"title":["Haemodialysis in haemophilia B: a case report. Challenges and strategies from a nephrology perspective"],"prefix":"10.1093","author":[{"given":"Chiara","family":"Terzo","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cCannizzaro\u201d Emergency Hospital , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Maccarrone","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cCannizzaro\u201d Emergency Hospital , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"La Rosa","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cSt. Giovanni Paolo II\u201d Hospital , Sciacca ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"Rare Hematological Disease Unit, \u201cG. Rodolico\u2014St. Marco\u201d University Hospital , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cCannizzaro\u201d Emergency Hospital , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072300280690700_aajag131-B1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/ejh.12134","article-title":"Renal diseases in haemophilic patients: pathogenesis and clinical management","volume":"91","author":"Esposito","year":"2013","journal-title":"Eur J Haematol"},{"key":"2026072300280690700_aajag131-B2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/ijot.ijot_49_20","article-title":"Managing end-stage renal disease and live kidney transplant in a patient with hemophilia A: a case report and review of literature","volume":"15","author":"Bhagat","year":"2021","journal-title":"Indian J Transpl."},{"key":"2026072300280690700_aajag131-B3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1046\/j.1351-8216.2003.00.0821.x","article-title":"Renal disease among males with haemophilia","volume":"9","author":"Kulkarni","year":"2003","journal-title":"Haemophilia"},{"key":"2026072300280690700_aajag131-B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/hae.12847","article-title":"Hypertension, haematuria and renal functioning in haemophilia\u2014a cross-sectional study in Europe","volume":"22","author":"Holme","year":"2016","journal-title":"Haemophilia"},{"key":"2026072300280690700_aajag131-B5","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1016\/j.ekir.2022.09.030","article-title":"End stage renal failure patients with hemophilia treated with peritoneal dialysis: a case series","volume":"7","author":"Zheng","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026072300280690700_aajag131-B6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/ndt\/gfm556","article-title":"Haemodialysis in a patient with haemophilia B","volume":"23","author":"Kusztal","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026072300280690700_aajag131-B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01872.x","article-title":"Dialysis in the haemophilia patient: a practical approach to care","volume":"15:33","author":"Agnello","year":"2009","journal-title":"Haemophilia"},{"key":"2026072300280690700_aajag131-B8","first-page":"170","article-title":"Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders","volume":"16","author":"Bajo","year":"2000","journal-title":"Adv Perit Dial"},{"key":"2026072300280690700_aajag131-B9","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/pbc.24340","article-title":"Hemophilia and prophylaxis","volume":"60","author":"Ljung","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026072300280690700_aajag131-B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","article-title":"KDOQI clinical practice guideline for vascular access: 2019 update","volume":"75","author":"Lok","year":"2020","journal-title":"Sono J Kidney Dis"},{"key":"2026072300280690700_aajag131-B11","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026072300280690700_aajag131-B12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/hematology.2022000387","article-title":"Perioperative hemostasis for patients with hemophilia","volume":"2022","author":"Poston","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026072300280690700_aajag131-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102169","article-title":"Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis","volume":"7","author":"Shapiro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026072300280690700_aajag131-B14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40620-024-02197-y","article-title":"SOLFA study: a multicenter, open-label, prospective, randomized study to investigate the clotting propensity of asymmetric cellulose triacetate membrane compared to synthetic membranes in on line HDF","volume":"38","author":"Puerta","year":"2025","journal-title":"J Nephrol"},{"key":"2026072300280690700_aajag131-B15","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ckj\/sfaa228","article-title":"Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study","volume":"14","author":"Vandenbosch","year":"2020","journal-title":"Clin Kidney J"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag131\/69837910\/aajag131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag131\/69837910\/aajag131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:28:12Z","timestamp":1784780892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag131\/8740177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag131","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"aajag131"}}